Abstract
Ovarian cancer remains the most lethal gynecological malignant tumor, with relapse
occurring in approximately 70% of advanced cases. Anlotinib is an oral small-molecule
multi-targeted tyrosine kinase inhibitor that can resist neoangiogenesis and inhibit tumor
growth. Previous research demonstrated clinical antitumor activity of anlotinib in various
cancers. We report the case of an elderly woman with advanced ovarian cancer who received
anlotinib after failure of multiple-line chemotherapy. A partial response was observed
after six cycles of anlotinib monotherapy, with a reduction in the size of the metastases
and significantly decreased serum CA125 levels from 1832.7 U/mL to 118.7 U/mL. She
continued to take anlotinib, with a progression-free survival time of more than 4 months.
Only mild hypertension was observed during the treatment. Anlotinib monotherapy may be a
novel therapeutic option for patients with advanced ovarian cancer.
Collapse